Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM - NDS-MM-004

Updated: 24 March, 2021   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • N/A


  • Gender(s)

  • 18+

    Age Range

  • 15


  • Recruiting

Treatment Options

Study Arms
Experimental: Patient App + HCP Portal (Cohort 1)
Device: MyHOPE™ for Multiple Myeloma Device: MyHope HCP Portal
Experimental: Patient App Alone (Cohort 2)
Device: MyHOPE™ for Multiple Myeloma

Key Eligibility Criteria

Inclusion Criteria: - Patient is ≥ 18 years old with a diagnosis of Multiple Myeloma - Patient must reside in the USA. - Patients within each of the following subgroups, at one of the following timepoints, will be eligible for entry: 1. Newly-diagnosed multiple myeloma transplant-eligible 2. Patients undergoing their first ASCT 3. Newly-diagnosed multiple myeloma transplant-ineligible 4. Relapsed and/or refractory. Exclusion Criteria: - Patient has a condition(s) that, in the opinion of the Investigator, would make participation infeasible such as inability to provide informed consent, illiteracy, or inability to speak, read, and write in English. - Patient is on hospice. - Patient is receiving or has received an investigational agent < 28 days prior to randomization or during this pilot study.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com